-
NAV$111.70
as of February 27, 2026 -
YTD RETURNS8.32%
as of February 27, 2026 -
Total Net Assets$1.31B
as of February 27, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
About PPH
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Overview
Why PPH
- Highly Liquid Companies: Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
- Industry Leaders: Index methodology favors the largest companies in the industry
- Global Scope: Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
Performance
Fees
Holdings
Portfolio
Sector Weightings (%) as at 31 Jan 2026
-
Sector
% of Net Assets -
Health Care
99.80 -
Other/Cash
0.20
Country Weightings (%) as at 31 Jan 2026
-
Country
% of Net Assets -
United States
60.80 -
United Kingdom
11.69 -
Switzerland
10.46 -
Denmark
7.28 -
France
4.07 -
Japan
2.76 -
Israel
2.75 -
Other/Cash
0.20